Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783248 | 0.86 | S1PR1 (0.45) | CA2GAAS1PR1 | |
| SCHEMBL478021 | 0.86 | S1PR1 (0.45) | CA2GAAS1PR1 | |
| SCHEMBL6755272 | 0.83 | CA2 (0.39) | CA2NR3C1NR3C2GAAPGR | |
| SCHEMBL7968048 | 0.81 | ALDH1A1 (0.43) | CA2GAAMEN1ALDH1A1KMT2A | |
| SCHEMBL15229537 | 0.76 | MBOAT4 (0.43) | CA2ALDH1A1KDM4EATM | |
| SCHEMBL30242157 | 0.76 | MBOAT4 (0.43) | CA2ALDH1A1KDM4EATM | |
| SCHEMBL30242156 | 0.76 | MBOAT4 (0.43) | CA2ALDH1A1KDM4EATM | |
| SCHEMBL6758820 | 0.75 | ACHE (0.52) | NR3C1NR3C2GAAPGRMEN1 | |
| SCHEMBL6358873 | 0.75 | CA2 (0.48) | CA2ALDH1A1KDM4EATM | |
| SCHEMBL1080853 | 0.74 | CA2 (0.68) | CA2ALDH1A1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720433-B2 | MOTILIN RECEPTOR ANTAGONIST; PHE-N-ME-VAL-(3-(3-METHYLINDOL-5-YL))ALA-NH2;PHE-N-ME-VAL-PHE( 3-ACETYL-4-HYDROXY)-NH2;PHE-N-ME-VAL-(3-(5-TERT-BUTYL-4-SULFAM OYL-2-FURYL))ALA-NH2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | disclosed |
| US-6586630-B1 | Carbocyclic carboxy amines, used as motilin receptor antagonists for therapy of gastrointerstinal disorders such as irritable bowel syndrome; hormone inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176643-A1 | Ethylamine derivatives | MLNR, GIPR, MC4R | CA2 3918/4885NR3C1 653/4885NR3C2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.